Is Vaccination Worthwhile Before Travel?

  • G. Wiedermann

Summary

Possible immunizations for travelers to developing countries may be divided into three categories: compulsory, commonly recommended and occasionally recommended immunizations. When trying to judge their beneficial effects we may do so from two points of view: by considering risk and benefit or cost and benefit. Calculations can be done by the introduction of simple mathematical formulas. In the case of risk-benefit calculations the risk-benefit ratio (Q) weighs risk of disease against risk of vaccination, which is recommendable if Q > 1.0. The risk-benefit difference considers preventable disease or complications. An immunization is recommendable if D > 0. Similarly, the cost-benefit ratio( Q c ) considers cost-effectiveness and the cost-benefit difference (D c ) presents the amount of money saved. Four examples have been chosen for these calculations: vaccination against cholera, tetanus and poliomyelitis and passive immunization against hepatitis A. In the case of cholera Q c < 1, indicating that this vaccination is not cost effective. However, Q is a bit more than 1 and D above O. Tetanus vaccination of people staying at home or travelling is recommendable and just cost-effective. Costs of OPV are being paid by the Austrian government; Q and D (risk-benefit parameters) are highly positive. Passive immunization against hepatitis A is recommendable and cost-effective for Austrian soldiers on UN mission. For the individual traveler it is cost-effective if the hepatitis risk is > 1:150.

Keywords

Hepatitis Europe Transportation Income Tuberculosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allard R (1983) Problems in adequately immunizing international travellers. Can Med Assoc J 127:40–41Google Scholar
  2. 2.
    Ambrosch F, Wiedermann G (1975) Mathematische Methoden zur Beurteilung des Nutzens von Schutzimpfungen. Immun Infekt 3:24–31PubMedGoogle Scholar
  3. 3.
    Ambrosch F, Wiedermann G, Wustinger E (1978) Klinische und laborchemische Untersuchungen zur Beurteilung der Gammaglobulinprophylaxe bei Tropenaufenthalten. Wien Med Wochenschr 128:625–627PubMedGoogle Scholar
  4. 4.
    Creese AL (1984) Cost effectiveness of alternative strategies for poliomyelitis immunization in Brazil. Rev Infect Dis [Suppl 2] 6:404–407CrossRefGoogle Scholar
  5. 5.
    Kollaritsch H, Ambrosch F, Aspöck H, Auer H, Picher O, Stemberger H, Ambrosch F, Wiedemann G (1982) Analyse der Ergebnisse von Tropenrückkehrun-tersuchungen. Mitt Osterr Ges Tropenmed Parasitol 4:127–134Google Scholar
  6. 6.
    Kudesia G, Follett EAC (1987) Not all travellers need immunoglobulin for hepatitis A. Br Med J 295:118CrossRefGoogle Scholar
  7. 7.
    Kunz H (1971) Tetanusprophylaxe - ein Gebot der ärztlichen Vorsorge. Osterr Arzte Z 26:758–763Google Scholar
  8. 8.
    Ohara H, Ebisawa I, Ohtani S (1986) Prophylactic efficacy of immune serum globulin against hepatitis A. Jpn J Exp Med 56:229–233PubMedGoogle Scholar
  9. 9.
    Steffen R (1984) Reisemedizin. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  10. 10.
    Steffen R, Regli P, Grob PJ (1977) Wie groß ist das Risiko einer Reisehepatitis? Schweiz Med Wochenschr 107:1300–1307PubMedGoogle Scholar
  11. 11.
    Tettmar RE, Masterton RG, Strike RW (1987) Hepatitis A immunity in British adults - an assessment of the need for pre-immunisation screening. J Infect 15:39–43PubMedCrossRefGoogle Scholar
  12. 12.
    Walker E, Williams G (1983) ABC of healthy travel. Immunisation I. Br Med J 286:629–631CrossRefGoogle Scholar
  13. 13.
    Walker E, Williams G (1983) ABC of healthy travel. Immunisation II. Br Med J 286:703–705CrossRefGoogle Scholar
  14. 14.
    WHO (1974) Cholera. Weekly Epidemiol Rec 32:269–270Google Scholar
  15. 15.
    WHO (1987) Poliomyelitis in 1985. Part I. WER 37:273–276Google Scholar
  16. 16.
    WHO (1987/1988) Vaccination certificate requirements and health advice for international travel. WHO, GenevaGoogle Scholar
  17. 17.
    Wiedermann G (1979) Moderne Trends im Impfwesen: Erfassung von Nutzen. Risiko und Kosten von Impfungen. Wien Klin Wochenschr 91:143–150PubMedGoogle Scholar
  18. 18.
    Wiedermann G, Ambrosch F (1974) Probleme von Impfungen. Wien Med Wochenschr 124:161–165PubMedGoogle Scholar
  19. 19.
    Wiedermann G, Ambrosch F (1979) Costs and benefits of immunization against measles and mumps. Bull WHO 57:625–629PubMedGoogle Scholar
  20. 20.
    Wiedermann G, Ambrosch F, Wustinger E, Gnan F (1978) Hepatitisprophylaxe mit Immunglobulin beim österreichischen UNO-Bataillon. Bundesgesundheitsblatt 21:467–471Google Scholar
  21. 21.
    Wiedermann G, Ambrosch F, Kollaritsch H, Kundi M (1984) Risks and benefits of vaccinations. Infect Control 5:438–444PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • G. Wiedermann

There are no affiliations available

Personalised recommendations